Survival effects of primary and metastatic surgical treatment in metastatic small intestinal tumors: A propensity score-matching study

PLoS One. 2022 Jun 24;17(6):e0270608. doi: 10.1371/journal.pone.0270608. eCollection 2022.

Abstract

Objective: To analyze the effects of primary tumor resection and metastatic lesion resection on the survival of metastatic small intestinal tumors.

Methods: The research subjects were patients with metastatic small bowel tumors identified from 2004 to 2016 in the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching and Kaplan-Meier analyses were performed to analyze the effect of surgery on the prognosis.

Results: A total of 4,034 patients from the SEER database were analyzed. Both before and after the propensity score-matching analysis, the prognosis of patients who underwent primary tumor surgery and metastatic surgery was better than that of patients who did not undergo surgery; all were patients with metastatic small bowel adenocarcinoma (mSIA) or metastatic small intestinal neuroendocrine tumors (mSI-NETs) (all p < .005). Patients with mSIA and adequate lymph node dissection had a longer prognosis than mSIA patients with inadequate lymph node dissection, but this survival benefit was not present in mSI-NET patients. It made no difference in the prognosis of mSIA and mSI-NETs whether localized surgery or intestine-ectomy was performed. Patients with mSIA who underwent primary and metastatic excision plus chemotherapy had the best overall survival and cancer-specific survival rates, whereas mSI-NET patients who underwent primary and metastatic excision had the best overall survival and cancer-specific survival rates (all p < .001).

Conclusion: In these carefully selected patients, primary tumor resection and/or metastatic lesion resection significantly improved the survival rates for patients with mSIA and mSI-NETs. The mSIA patients with resectable primary tumors seemed to require a sufficient number of lymph node dissections more than the patients with well-differentiated mSI-NETs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / surgery
  • Duodenal Neoplasms* / pathology
  • Humans
  • Intestinal Neoplasms* / pathology
  • Lymph Node Excision / methods
  • Neoplasm Staging
  • Neuroendocrine Tumors* / pathology
  • Prognosis
  • Propensity Score
  • Retrospective Studies
  • SEER Program

Grants and funding

The author, DW, has received funding from the China Scholarship Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.